ArticleQuantitative imaging in medicine and surgery2025
Predicting the regrowth of residual uterine fibroids after high-intensity focused ultrasound treatment: an interpretable magnetic resonance imaging radiomics model.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Model Based on Ultrasound Radiomics and Machine Learning for Differentiating Uterine Fibroids and Adenomyomas.Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine · 2026Article
- FibroidX: Vision Transformer-Powered Prognosis and Recurrence Prediction for Uterine Fibroids Using Ultrasound Images.Cancers · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The evaluation of residual uterine fibroids (RFs) after magnetic resonance imaging (MRI)-based radiomics is complex, making it challenging to accurately predict and interpret the regrowth of RFs following high-intensity focused ultrasound (HIFU) treatment. Therefore, the aim of this research was to establish a robust multiparametric radiomics model which functions to predict the regrowth of RFs following HIFU treatment. Moreover, SHapley Additive exPlanations (SHAP) was adopted to clarify the internal prediction process of the model. Methods: In this retrospective investigation, 116 patients diagnosed with uterine fibroids who underwent HIFU treatment were enrolled, and underwent follow-up imaging approximately one-year post-treatment. Patients were categorized into RF regrowth and non-regrowth groups based on the occurrence of residual fibroid regrowth 1 year after treatment. The cohort was divided into a training set (N=92) and a test set (N=24). A total of 218 radiomic features were acquired from T2-weighted imaging (T2WI) and contrast-enhanced T1-weighted imaging (CE-T1WI) scans. Subsequent to the implementation of preprocessing and feature selection steps, logistic regression (LR) models were developed using radiomic features from T2WI and CE-T1WI, as well as a feature-level fusion of both. Finally, the SHAP approach was applied to interpret the underlying predictive mechanisms. Results: The LR models achieved areas under the curve (AUCs) of 0.926 [95% confidence interval (CI): 0.817-1.000] for the T2WI model, 0.879 (95% CI: 0.731-1.000) for the CE-T1WI model, and 0.946 (95% CI: 0.897-0.995) for the fusion model. The SHAP technology was employed to facilitate clinicians' comprehension of the influence exerted by radiomic features on the model's predictions from both global and individual perspectives. Conclusions: The multiparametric radiomics model demonstrated robustness in predicting the regrowth of RFs post-HIFU treatment. Radiomic features may serve as potential biomarkers for preoperative evaluation for HIFU treatment and enhance the mechanism of RF regrowth after HIFU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.